By admin 
The Federal Trade Commission has launched an expansive investigation into Epic Systems Corp., the dominant force in the United States electronic health records market, to determine whether the company’s business practices violate federal antitrust laws. According to sources familiar with the matter, federal investigators have begun contacting healthcare executives, consultants, and technology rivals to gather evidence regarding Epic’s market conduct. The probe, while in its preliminary stages, signals a significant escalation in the government’s scrutiny of the "Big Tech" players within the healthcare sector, focusing on how the control of patient data and the restriction of labor mobility may be stifling competition in an industry vital to the national economy.
Epic Systems, headquartered on a sprawling, whimsical campus in Verona, Wisconsin, is the undisputed leader of the electronic health record (EHR) industry. Founded by billionaire Judy Faulkner in 1979, the company has grown from a small basement operation into a behemoth that holds the medical records of more than 300 million people worldwide. In the United States, Epic’s software is the backbone of nearly nearly all major academic medical centers and the vast majority of large health systems, including the Mayo Clinic, Cleveland Clinic, and Kaiser Permanente. As of recent market share reports, Epic controls over 36% of the acute care hospital market and a staggering 50% of all hospital beds in the country. This dominance has long made Epic a target of criticism from smaller competitors who argue that the company’s "walled garden" approach makes it difficult for third-party innovations to integrate with hospital systems.
The FTC’s inquiry appears to be bifurcated, addressing two distinct but interconnected pillars of Epic’s business strategy. The first line of questioning revolves around Epic’s restrictive employment agreements. For years, Epic has been known for its stringent non-compete clauses and "no-poach" arrangements that prevent former employees—and often the employees of its customers—from moving to rival firms or starting competing ventures for a specified period. These agreements are not limited to direct competitors; they often extend to a broad swath of the healthcare consulting and technology landscape. Investigators are reportedly looking into whether these practices artificially suppress wages, limit the pool of available talent for competitors, and prevent the cross-pollination of ideas that drives innovation in the health tech space.
This focus on labor mobility aligns with the broader priorities of the FTC under Chair Lina Khan, who has made the elimination of non-compete agreements a cornerstone of her tenure. In early 2024, the FTC issued a final rule aimed at banning most non-compete clauses nationwide, arguing they are an unfair method of competition. While that rule has faced legal challenges in various federal courts, the investigation into Epic suggests the commission is willing to use its enforcement powers to target specific industry leaders whose labor practices may have outsized impacts on market dynamics. For Epic, a company that prides itself on its unique internal culture and proprietary knowledge, these labor restrictions have been a key mechanism for maintaining its competitive edge.
The second, and perhaps more complex, prong of the FTC’s probe focuses on "data blocking" and the leveraging of market power to disadvantage rival technology providers. In the modern healthcare landscape, data is the most valuable commodity. For a startup developing a new AI-driven diagnostic tool or a specialized patient monitoring app to succeed, it must be able to pull data from and push data to the primary EHR system used by the hospital. Witnesses contacted by the FTC have alleged that Epic uses its position as the primary gatekeeper of patient information to make it difficult, expensive, or technically cumbersome for third-party software to interoperate with its platform.
Critics argue that while Epic has made strides in interoperability through its "Care Everywhere" network, which allows Epic-to-Epic data sharing, it remains notoriously difficult for "Epic-to-Other" exchanges. This creates a "vendor lock-in" effect, where hospitals are hesitant to adopt new, innovative technologies from other vendors because the cost and technical headache of integrating them with Epic are too high. There are also concerns regarding Epic’s "App Orchard" (now rebranded as "Showroom"), a marketplace for third-party developers. Some developers have complained that Epic charges high fees, imposes restrictive terms of service, and maintains the power to pick winners and losers by deciding which apps are allowed to interface deeply with its core software.
The legal framework for this part of the investigation likely rests on the 21st Century Cures Act, which was passed by Congress in 2016 with the explicit goal of ending "information blocking." The Department of Health and Human Services (HHS) has since established rules that penalize providers and developers who interfere with the lawful access, exchange, or use of electronic health information. However, the FTC’s interest suggests a move beyond mere regulatory compliance into the realm of antitrust, looking at whether Epic’s behavior constitutes an illegal maintenance of a monopoly. If Epic is found to be using its dominance in the EHR market to gain an unfair advantage in adjacent markets—such as population health management, telehealth, or revenue cycle management—it could face severe penalties or forced changes to its business model.
Epic has historically defended its practices by emphasizing the need for data security, patient privacy, and the integrity of its integrated system. The company argues that its "one-database" approach is superior for patient safety because it ensures that a patient’s information is consistent across all departments of a hospital. Judy Faulkner has been a vocal critic of certain federal interoperability mandates, once famously lobbying against rules that she argued would compromise patient privacy by making it too easy for third-party apps to scrape sensitive medical data.
However, the tide of industry sentiment has been shifting. As healthcare costs continue to spiral, policymakers are increasingly looking at the role of technology in either exacerbating or alleviating those costs. A lack of competition in the EHR space is often cited as a reason for the high price of medical software and the "burnout" experienced by clinicians who must navigate complex, often unintuitive interfaces. If the FTC can prove that Epic’s market power is being used to keep prices high or quality low by preventing better alternatives from emerging, it would have a strong case for antitrust intervention.
The implications of this probe extend far beyond Epic’s headquarters. The entire healthcare IT industry is watching closely, as a successful challenge to Epic’s business model could open the floodgates for a new era of "open" health data. For years, the EHR market has been characterized by consolidation, with Epic and its primary rival, Oracle Health (formerly Cerner), absorbing much of the market share. If the FTC enforces stricter rules on interoperability and labor mobility, it could provide the necessary breathing room for smaller, more agile startups to challenge the incumbents.
Furthermore, the investigation comes at a time when Epic is expanding its reach into the world of artificial intelligence and large-scale data analytics. The company’s "Cosmos" database, which aggregates de-identified data from tens of millions of patients across its network, is being marketed as a revolutionary tool for medical research and precision medicine. While the potential benefits for public health are immense, the concentration of such a vast amount of data in the hands of a single private corporation raises significant antitrust and ethical questions. If Epic is the only company with the scale to train advanced medical AI models, it could cement its monopoly for decades to come.
The FTC’s move against Epic is also reflective of a global trend toward scrutinizing "ecosystem" platforms. Much like the investigations into Apple’s App Store or Google’s search dominance, the Epic probe asks whether a platform owner can fairly compete against the very companies that rely on that platform to survive. In the context of healthcare, where the stakes are literally life and death, the government’s interest in ensuring a fair and competitive marketplace is heightened.
As the probe continues, investigators are expected to dive deep into Epic’s contracts with hospital systems. These contracts often contain clauses that make it difficult for hospitals to switch vendors or to use certain "best-of-breed" software from other companies. By analyzing the economic incentives and penalties baked into these agreements, the FTC will attempt to build a narrative of "exclusionary conduct"—a key element in antitrust litigation.
The road ahead for the FTC is fraught with challenges. Antitrust cases against tech companies are notoriously difficult to win and can take years to move through the court system. Epic is a formidable opponent with deep pockets and a loyal customer base of hospital CEOs who have invested hundreds of millions of dollars into the Epic ecosystem. Any attempt to "break up" or significantly alter Epic’s operations will likely be met with fierce legal and political resistance.
Nevertheless, the mere existence of the investigation marks a turning point. For decades, Epic Systems has operated with relatively little interference from federal antitrust regulators, benefiting from a "first-mover" advantage and a product that became an essential utility for the American medical system. Now, as the government seeks to redefine the rules of the digital economy, the "Epic era" of healthcare IT may be entering its most turbulent chapter yet. The outcome of this inquiry will not only determine the future of one company but will shape the technological landscape of American medicine for the next generation, potentially deciding whether the future of healthcare data is a closed, proprietary secret or an open, competitive utility.
